NCT06721442View on ClinicalTrials.gov

Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study

PHASE4CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

December 10, 2023

Study Completion Date

July 10, 2024

Conditions
Arrhythmias, CardiacDiabetes Mellitus
Interventions
DRUG

Dapagliflozin (DAPA)

Patients randomized to receive a daily dose of 10 milligrams of dapagliflozin were evaluated to assess the medication's impact on electrocardiographic parameters of repolarization, with focus on its potential to reduce ventricular repolarization prolongation in individuals with type 2 diabetes.

Trial Locations (2)

Unknown

Hospital Beneficencia Portuguesa de São Paulo, São Paulo

Instituto Dante Pazzanese de Cardiologia, São Paulo

All Listed Sponsors
collaborator

Instituto Dante Pazzanese de Cardiologia

OTHER

lead

Beneficência Portuguesa de São Paulo

OTHER